Related Experiment Video
Updated: Jun 30, 2026
Real-Time Monitoring of Human Glioma Cell Migration on Dorsal Root Ganglion Axon-Oligodendrocyte Co-Cultures
Published on: December 13, 2019
PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion
Sebastian Seufert1, Roland Coras, Christian Tränkle
1Institute of Human Genetics, Institute of Genetics, and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Kerpener Street 34, 50931 Cologne, Germany.
Abstract:
Today, there is increasing evidence that PPARgamma agonists, including thiazolidinediones (TDZs) and nonthiazolidinediones, block the motility and invasiveness of glioma cells and other highly migratory tumor entities. However, the mechanism(s) by which PPARgamma activators mediate their antimigratory and anti-invasive properties remains elusive. This letter gives a short review on the debate and adds to the current knowledge by applying a PPARgamma inactive derivative of the TDZ troglitazone (Rezulin) which potently counteracts experimental glioma progression in a PPARgamma independent manner.
Insights
PPARgamma agonists inhibit glioma cell migration, but the mechanism is unclear. A troglitazone derivative blocked glioma progression independently of PPARgamma, suggesting novel therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists, such as thiazolidinediones (TDZs), are known to inhibit the motility and invasiveness of glioma cells.
- The precise molecular mechanisms underlying the anti-migratory and anti-invasive effects of PPARgamma activators are not fully understood.
- This study investigates the role of PPARgamma in glioma progression and therapeutic resistance.
Purpose of the Study:
- To review the current understanding of PPARgamma's role in blocking glioma cell motility and invasiveness.
- To explore potential PPARgamma-independent mechanisms contributing to the inhibition of glioma progression.
- To evaluate the efficacy of a PPARgamma-inactive derivative of troglitazone in counteracting experimental glioma progression.
Main Methods:
- Review of existing literature on PPARgamma agonists and glioma cell behavior.
- Application of a PPARgamma-inactive derivative of troglitazone (a TDZ) in experimental glioma models.
- Assessment of glioma cell motility, invasiveness, and overall tumor progression.
Main Results:
- PPARgamma agonists demonstrate inhibitory effects on glioma cell motility and invasiveness.
- A PPARgamma-inactive derivative of troglitazone effectively counteracted experimental glioma progression.
- The observed anti-glioma effects of the troglitazone derivative occurred independently of PPARgamma activation.
Conclusions:
- The findings suggest that PPARgamma-independent pathways are involved in mediating the anti-migratory and anti-invasive properties observed with certain PPARgamma agonists.
- This research opens new avenues for developing therapeutic strategies targeting glioma progression through non-PPARgamma-dependent mechanisms.
- Further investigation into these PPARgamma-independent pathways could lead to novel treatments for highly migratory tumors.
